$Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study$

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study

Bibliographic Details
Main Authors:	Yan-Yan Li, Shuai-Shuai Ge, Yuan-Hong Huang, Ming-Zhu Xu, Chao-Ling Wan, Kai-Wen Tan, Tao Tao, Hai-Xia Zhou, Sheng-Li Xue, Hai-Ping Dai
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-01-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-024-00982-3

Similar Items

A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia
by: Reza Safaei Nodehi, et al.
Published: (2010-03-01)

A Study of the Complete Response Rate with a Combination of High Dose Cytarabine and Cladribine in Refractory and Relapsed Acute Leukemia
by: Reza Safaei Nodehi, et al.
Published: (2010-01-01)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
by: Linyu Yuan, et al.
Published: (2023-08-01)

P592: GILTERITINIB IN COMBINATION WITH VENETOCLAX, LOW DOSE CYTARABINE AND ACTINOMYCIN D FOR FLT3 MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
by: A. Žučenka, et al.
Published: (2022-06-01)

Clinical Study of Venetoclax with Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
by: CHEN Xiaofeng, WANG Meng, LI Zhongyu, LI Jiajia
Published: (2022-03-01)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
by: Baohang Zhang, et al.
Published: (2023-05-01)

Cladribine and cytarabine in children refractory high risk multisystem Langerhans cell histiocytosis
by: Wenqian Wang, et al.
Published: (2023-09-01)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
by: Serena Brancati, et al.
Published: (2021-12-01)

Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re‐induction chemotherapy
by: Min Ruan, et al.
Published: (2021-02-01)

P500: SUPERIOR OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AMONG PATIENTS ≥ 60 YEARS TREATED WITH CLADRIBINE, LOW DOSE CYTARABINE PLUS VENETOCLAX FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: Jayastu Senapati, et al.
Published: (2023-08-01)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
by: Rie Nishi, et al.
Published: (2020-10-01)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
by: Xiao Han, et al.
Published: (2023-08-01)

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
by: Jorge Labrador, et al.
Published: (2022-03-01)

The Role of Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Past, Present, and Future Directions
by: Matteo Piccini, et al.
Published: (2023-05-01)

A real-world study on Clofarabine and Cytarabine combination in patients with relapsed/refractory acute myeloid leukemia
by: Claudio Fozza, et al.
Published: (2019-04-01)

Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis
by: Zhou A, et al.
Published: (2019-05-01)

Venetoclax Combined with Intensive Chemotherapy: A New Hope for Refractory and/or Relapsed Acute Myeloid Leukemia?
by: Ramy Rahmé, et al.
Published: (2024-01-01)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
by: Xubo Gong, et al.
Published: (2024-02-01)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
by: Zheng Li, et al.
Published: (2022-02-01)

Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia
by: E. V. Usikova, et al.
Published: (2023-01-01)

Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
by: Xubo Gong, et al.
Published: (2023-06-01)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
by: Prajwal Boddu, et al.
Published: (2018-09-01)

Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial
by: Chengtao Zhang, et al.
Published: (2023-08-01)

Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax
by: Thao M. Nguyen, et al.
Published: (2024-01-01)

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
by: Louise Laloi, et al.
Published: (2023-03-01)

Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
by: Xuezhu Xu, et al.
Published: (2023-12-01)

Cladribine Combined with Low-Dose Cytarabine as Frontline Treatment for Unfit Elderly Acute Myeloid Leukemia Patients: Results from a Prospective Multicenter Study of Polish Adult Leukemia Group (PALG)
by: Bożena Katarzyna Budziszewska, et al.
Published: (2021-08-01)

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
by: Joshua F. Zeidner, et al.
Published: (2021-10-01)

PB1784: CLADRIBINE SYNERGIZES THE EFFECT OF VENETOCLAX ON CELL PROLIFERATION ARREST AND APOPTOSIS BY TARGETING DNA-PKCS/C-MYC SIGNALING IN ACUTE MYELOID LEUKEMIA
by: Yue Hou, et al.
Published: (2023-08-01)

Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome‐positive acute myeloid leukemia: A case report
by: Si‐Man Huang, et al.
Published: (2023-01-01)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
by: Harinder Gill, et al.
Published: (2020-05-01)

P540: PEVONEDISTAT, AZACITIDINE AND VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA– A PHASE I STUDY
by: G. S. Guru Murthy, et al.
Published: (2022-06-01)

P568: REAL-LIFE EXPERIENCE OF TREATMENT REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA PATIENTS WITH VENETOCLAX COMBINATION THERAPY
by: H. Pomares Marin, et al.
Published: (2022-06-01)

Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome: Bursa Uludag University Experience
by: İbrahim Ethem Pınar, et al.
Published: (2021-03-01)

P578: EFFECTIVENESS OF REINDUCTION CHEMOTHERAPY USING BORTEZOMIB WITH HOMOHARRINGTONINE AND CYTARABINE IN REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA: A PHASE II, MULTICENTER, PROSPECTIVE CLINICAL TRIAL
by: Chengtao Zhang, et al.
Published: (2023-08-01)

P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA
by: J. Senapati, et al.
Published: (2022-06-01)

Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience
by: Francesco Angotzi, et al.
Published: (2024-04-01)

P510: PREDICTORS OF RESPONSE AND OUTCOME IN PATIENTS WITH REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA RECEIVING VENETOCLAX WITH NON-INTENSIVE CHEMOTHERAPY
by: Katja Krüger, et al.
Published: (2023-08-01)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
by: Matthew E. Tenold, et al.
Published: (2021-03-01)

Venetoclax in adult acute myeloid leukemia
by: Mengci Hu, et al.
Published: (2023-12-01)